Affymax Promotes Krishna R. Polu, M.D. to Vice President, Clinical Development

PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (NASDAQ:AFFY) today announced the promotion of Krishna Polu, M.D. to vice president, Clinical Development. Dr. Polu, a nephrologist, joined Affymax in 2009 as executive director, Clinical Development.

“I am pleased to recognize Krishna’s significant leadership over the past two years, including his contributions to our recently accepted New Drug Application which is under review at the FDA,” said Anne-Marie Duliege, M.D., chief medical officer of Affymax. “We look forward to his continued leadership and support as we progress through the FDA review process and prepare for potential commercialization of peginesatide.”

Prior to joining Affymax, Dr. Polu was executive director, Global Development at Amgen where he was responsible for clinical programs in nephrology, diabetes and heart failure. Specifically, he led the global clinical development programs for both EPOGEN and Aranesp while at Amgen. Before joining Amgen, he was a clinical and research fellow at Harvard Medical School in the Renal Division at Brigham and Women’s Hospital and Massachusetts General Hospital. He earned a B.A. in Human Biology from Stanford University and a M.D. from University of Texas Health Science Center, San Antonio. He completed his residency training in Internal Medicine at the University of Colorado.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. For additional information, please visit www.affymax.com.

This release contains forward-looking statements, including statements regarding milestones expected to be accomplished, progress of the peginesatide development program and the timing and potential regulatory approval and commercialization of peginesatide. Affymax’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties, including risks relating to the approvability and completeness of the New Drug Application (NDA) filing, risks relating to regulatory requirements and approvals, in particular the FDA’s interpretation and review of the data in the NDA including issues related to the subgroup analyses in non-dialysis, data quality and integrity particularly in non-inferiority designed trials, the continued safety and efficacy of peginesatide in clinical development, the timing of patient accrual in ongoing and planned clinical studies, research and development efforts, industry and competitive environment, intellectual property rights and disputes and potential for costs, disruptions and consequences of litigation, financing requirements and ability to access capital and other matters that are described in Affymax's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Affymax undertakes no obligation to update any forward-looking statement in this press release.



CONTACT:

Affymax, Inc.
Sylvia Wheeler, 650-812-8861
Vice President, Corporate Communications

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.